Obicetrapib is a CETP inhibitor that is intended to treat dyslipidemia. Obicetrapib is a lipid-modifying agent that blocks a blood protein called CETP, thereby lowering the level of LDL cholesterol. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
The most common side effects include hypertension, dizziness, headache, diarrhea, and abdominal pain.
History Obicetrapib was initially developed by Amgen as AMG-899 and was abandoned in 2017.Amgen kills off CETP inhibitor after seeing Merck data In 2020, Amgen licensed the drug to NewAmsterdam Pharma.NewAmsterdam bags $196M to resurrect Amgen's discarded CETP drug In 2022, NewAmsterdam Pharma licensed the drug to Menarini Group.
In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C (by up to 51%), apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) (by up to 44%), and increased HDL-C concentration (by up to 165%).
Obicetrapib's ability to lower LDL cholesterol (“bad” cholesterol) compared with placebo was observed in two 52-week, randomized, double-blind, placebo-controlled studies in adults with high cholesterol and/or mixed dyslipidemia who were already receiving the maximum tolerated cholesterol-lowering treatment.
Society and culture Legal status On Sept 21,2026 the European Commission granted marketing authorisation to NewAmsterdam and Menarini for Ubeslo (obicetrapib 10mg monotherapy) and Evlarco (10mg obicetrapib plus 10mg ezetimibe fixed-dose combination).
Names Obicetrapib is the International nonproprietary name.
References